Lecanemab was designed to attach to the beta protofibrils to block the formation of plaques. USFDA granted a traditional approval to it on July 16, 2023. Its side effects are less severe and the efficacy is more consistent than acucanamub in most clinical trials. It was found to reduce the cognitive deficiency up to 26% in the group of early stage Alzheimer’s disease. The cost was up to USD 26500 for a year; however, it will be covered by Medicare.